Improving treatments for non-small cell lung cancer
Emory University Lung Cancer SPORE
This study is looking at new ways to make immunotherapy work better for people with non-small cell lung cancer by exploring how certain immune cells and targets can help overcome treatment challenges, so patients might have access to improved therapies that lead to better results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10685410 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of immunotherapy and overcoming treatment resistance in patients with non-small cell lung cancer (NSCLC). A multidisciplinary team of experts will investigate the role of specific immune cells and molecular targets to develop new treatment strategies. The research aims to evaluate stem-like T cells to improve checkpoint inhibitors, target MERTK for EGFR-mutated NSCLC, and address treatment resistance through Bax signaling. Patients may benefit from innovative therapies that could lead to better outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer, particularly those with advanced stages or specific mutations.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with cancer may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for non-small cell lung cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in enhancing immunotherapy and targeting specific molecular pathways in lung cancer, indicating that this approach has potential for success.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Ramalingam, Suresh S — Emory University
- Study coordinator: Ramalingam, Suresh S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.